Fundraising Fox
Damoratx
Founded 2025 · 44 employees on LinkedIn · 2 known investors
Find your way into Damoratx
Sign up to see every warm intro you have to Damoratx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Damoratx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations. The company is advancing novel subcutaneous biologics to treat approximately 42,000 U.S. patients with these myeloproliferative neoplasms.
Founders & leadership
SS
Sherwin SattarzadehChief Operating OfficerSherwin Sattarzadeh is Chief Operating Officer of Damora Therapeutics, bringing over 20 years of experience in biotechnology and pharmaceutical development across multiple therapeutic areas, including roles managing drug development, clinical strategy, and business operations.
BH
Becker HewesChief Medical Officer
Investors · 2
Frequently asked questions
- What does Damoratx do?
- Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations. The company is advancing novel subcutaneous biologics to treat approximately 42,000 U.S. patients with these myeloproliferative neoplasms.
- Who are Damoratx's investors?
- Damoratx's investors include TCG Crossover, Wellington Management.